Investor Relations, Videos April 18, 2024 Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device Read More
Investor Relations April 9, 2024 Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing Read More
Investor Relations April 4, 2024 Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device Read More
Investor Relations April 2, 2024 Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board Read More
Investor Relations March 28, 2024 Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego Read More
Investor Relations March 14, 2024 Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology Read More